Brief: PolyPid Announces Eligibility For European Medicines Agency Centralized Procedure For D-Plex₁₀₀ For The Prevention Of Surgical Site Infections In Abdominal Surgery
28/09/2022 14:08
Sept 28 (Reuters) - PolyPid Ltd PYPD.O :
* POLYPID ANNOUNCES ELIGIBILITY FOR EUROPEAN MEDICINES
AGENCY
CENTRALIZED PROCEDURE FOR D-PLEX₁₀₀ FOR THE PREVENTION OF
SURGICAL SITE INFECTIONS IN ABDOMINAL SURGERY
* POLYPID LTD - D-PLEX100 IS ELIGIBLE FOR CENTRALIZED
PROCEDURE
UNDER THERAPEUTIC INNOVATION CRITERIA
* POLYPID LTD - INTEND TO DISCUSS DATA AND POTENTIAL NEXT
STEPS
WITH U.S. AND EU REGULATORY AUTHORITIES IN Q1 OF 2023
* POLYPID LTD - CURRENTLY FURTHER EVALUATING TOP-LINE
RESULTS OF
SHIELD I
Source text for Eikon: ID:nGNX2ZBkKY
Further company coverage: PYPD.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Polypid
See all newsPolyPid Ltd reports results for the quarter ended June 30 - Earnings Summary
PolyPid Ltd expected to post a loss of 38 cents a share - Earnings Preview
Brief: Polypid Announces FDA Acceptance Of NDA With Priority Review For D-Plex₁₀₀
PolyPid, Azurity sign surgical site infection drug deal
Brief: Polypid Initiates D-Plex₁₀₀ NDA Submission To The FDA